S&P 500   3,261.78 (+0.47%)
DOW   26,871.26 (+0.21%)
QQQ   268.95 (+1.34%)
AAPL   110.55 (+2.15%)
MSFT   206.82 (+1.79%)
FB   251.59 (+0.83%)
GOOGL   1,427.88 (+0.35%)
AMZN   3,052.27 (+1.08%)
TSLA   404.92 (+4.42%)
NVDA   507.30 (+2.71%)
BABA   267.69 (-0.76%)
CGC   13.97 (-2.10%)
GE   6.04 (-0.33%)
MU   48.42 (-2.12%)
AMD   76.90 (+1.42%)
T   27.86 (-0.64%)
F   6.55 (-1.65%)
ACB   5.00 (-3.85%)
GILD   62.16 (-0.14%)
NFLX   478.06 (+1.05%)
DIS   122.49 (+0.00%)
BAC   23.29 (-0.21%)
BA   150.92 (+3.33%)
S&P 500   3,261.78 (+0.47%)
DOW   26,871.26 (+0.21%)
QQQ   268.95 (+1.34%)
AAPL   110.55 (+2.15%)
MSFT   206.82 (+1.79%)
FB   251.59 (+0.83%)
GOOGL   1,427.88 (+0.35%)
AMZN   3,052.27 (+1.08%)
TSLA   404.92 (+4.42%)
NVDA   507.30 (+2.71%)
BABA   267.69 (-0.76%)
CGC   13.97 (-2.10%)
GE   6.04 (-0.33%)
MU   48.42 (-2.12%)
AMD   76.90 (+1.42%)
T   27.86 (-0.64%)
F   6.55 (-1.65%)
ACB   5.00 (-3.85%)
GILD   62.16 (-0.14%)
NFLX   478.06 (+1.05%)
DIS   122.49 (+0.00%)
BAC   23.29 (-0.21%)
BA   150.92 (+3.33%)
S&P 500   3,261.78 (+0.47%)
DOW   26,871.26 (+0.21%)
QQQ   268.95 (+1.34%)
AAPL   110.55 (+2.15%)
MSFT   206.82 (+1.79%)
FB   251.59 (+0.83%)
GOOGL   1,427.88 (+0.35%)
AMZN   3,052.27 (+1.08%)
TSLA   404.92 (+4.42%)
NVDA   507.30 (+2.71%)
BABA   267.69 (-0.76%)
CGC   13.97 (-2.10%)
GE   6.04 (-0.33%)
MU   48.42 (-2.12%)
AMD   76.90 (+1.42%)
T   27.86 (-0.64%)
F   6.55 (-1.65%)
ACB   5.00 (-3.85%)
GILD   62.16 (-0.14%)
NFLX   478.06 (+1.05%)
DIS   122.49 (+0.00%)
BAC   23.29 (-0.21%)
BA   150.92 (+3.33%)
S&P 500   3,261.78 (+0.47%)
DOW   26,871.26 (+0.21%)
QQQ   268.95 (+1.34%)
AAPL   110.55 (+2.15%)
MSFT   206.82 (+1.79%)
FB   251.59 (+0.83%)
GOOGL   1,427.88 (+0.35%)
AMZN   3,052.27 (+1.08%)
TSLA   404.92 (+4.42%)
NVDA   507.30 (+2.71%)
BABA   267.69 (-0.76%)
CGC   13.97 (-2.10%)
GE   6.04 (-0.33%)
MU   48.42 (-2.12%)
AMD   76.90 (+1.42%)
T   27.86 (-0.64%)
F   6.55 (-1.65%)
ACB   5.00 (-3.85%)
GILD   62.16 (-0.14%)
NFLX   478.06 (+1.05%)
DIS   122.49 (+0.00%)
BAC   23.29 (-0.21%)
BA   150.92 (+3.33%)
Log in
NASDAQ:AYTU

Aytu Bioscience Stock Forecast, Price & News

$1.16
-0.04 (-3.33 %)
(As of 09/25/2020 10:34 AM ET)
Add
Compare
Today's Range
$1.16
Now: $1.16
$1.18
50-Day Range
$0.98
MA: $1.22
$1.42
52-Week Range
$0.34
Now: $1.16
$2.99
Volume8,441 shs
Average Volume11.83 million shs
Market Capitalization$139.91 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.18
Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia. It also offers MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. In addition, the company provides MiOXSYS analyzer, a portable lightweight desktop platform that is used in clinical or research laboratory or near a patient care area; and MiOXSYS disposable sensors. The company is based in Englewood, Colorado.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AYTU
CUSIPN/A
CIKN/A
Phone720-437-6580

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.32 million
Book Value$0.43 per share

Profitability

Net Income$-27,130,000.00
Net Margins-172.62%

Miscellaneous

Employees52
Market Cap$139.91 million
Next Earnings DateN/A
OptionableNot Optionable
$1.16
-0.04 (-3.33 %)
(As of 09/25/2020 10:34 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AYTU News and Ratings via Email

Sign-up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aytu Bioscience (NASDAQ:AYTU) Frequently Asked Questions

How has Aytu Bioscience's stock price been impacted by Coronavirus?

Aytu Bioscience's stock was trading at $1.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AYTU stock has decreased by 14.1% and is now trading at $1.16.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aytu Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aytu Bioscience
.

How were Aytu Bioscience's earnings last quarter?

Aytu Bioscience Inc (NASDAQ:AYTU) posted its quarterly earnings results on Thursday, May, 14th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.07. The company earned $8.16 million during the quarter, compared to the consensus estimate of $7 million. Aytu Bioscience had a negative net margin of 172.62% and a negative return on equity of 107.69%.
View Aytu Bioscience's earnings history
.

When did Aytu Bioscience's stock split? How did Aytu Bioscience's stock split work?

Shares of Aytu Bioscience reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of Aytu Bioscience stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for AYTU?

2 brokers have issued 1 year target prices for Aytu Bioscience's stock. Their forecasts range from $3.00 to $5.00. On average, they anticipate Aytu Bioscience's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 244.8% from the stock's current price.
View analysts' price targets for Aytu Bioscience
.

Are investors shorting Aytu Bioscience?

Aytu Bioscience saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 5,330,000 shares, a decrease of 12.0% from the August 15th total of 6,060,000 shares. Based on an average daily volume of 5,690,000 shares, the short-interest ratio is presently 0.9 days.
View Aytu Bioscience's Short Interest
.

Who are some of Aytu Bioscience's key competitors?

What other stocks do shareholders of Aytu Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu Bioscience investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Heat Biologics (HTBX), ADMA Biologics (ADMA), Inovio Pharmaceuticals (INO), Ibio (IBIO), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), BioNano Genomics (BNGO) and Novan (NOVN).

Who are Aytu Bioscience's key executives?

Aytu Bioscience's management team includes the following people:
  • Mr. Joshua R. Disbrow, Chairman & CEO (Age 44)
  • Mr. David A. Green, CFO, Sec. & Treasurer (Age 56)
  • Mr. Jarrett T. Disbrow, Chief Operating Officer (Age 44)

What is Aytu Bioscience's stock symbol?

Aytu Bioscience trades on the NASDAQ under the ticker symbol "AYTU."

Who are Aytu Bioscience's major shareholders?

Aytu Bioscience's stock is owned by a number of retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.24%), Bank of America Corp DE (0.21%), Nuveen Asset Management LLC (0.17%), Virtu Financial LLC (0.08%), Commonwealth Equity Services LLC (0.07%) and Bank of New York Mellon Corp (0.06%). Company insiders that own Aytu Bioscience stock include Armistice Capital Master Fund, David A Green and Joshua R Disbrow.
View institutional ownership trends for Aytu Bioscience
.

Which institutional investors are selling Aytu Bioscience stock?

AYTU stock was sold by a variety of institutional investors in the last quarter, including Searle & CO., and Goldman Sachs Group Inc..
View insider buying and selling activity for Aytu Bioscience
.

Which institutional investors are buying Aytu Bioscience stock?

AYTU stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Nuveen Asset Management LLC, Bank of America Corp DE, Virtu Financial LLC, Bank of New York Mellon Corp, New York State Common Retirement Fund, Commonwealth Equity Services LLC, and Charles Schwab Investment Management Inc.. Company insiders that have bought Aytu Bioscience stock in the last two years include Armistice Capital Master Fund, and Joshua R Disbrow.
View insider buying and selling activity for Aytu Bioscience
.

How do I buy shares of Aytu Bioscience?

Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aytu Bioscience's stock price today?

One share of AYTU stock can currently be purchased for approximately $1.16.

How big of a company is Aytu Bioscience?

Aytu Bioscience has a market capitalization of $139.91 million and generates $7.32 million in revenue each year. The company earns $-27,130,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. Aytu Bioscience employs 52 workers across the globe.

What is Aytu Bioscience's official website?

The official website for Aytu Bioscience is aytubio.com.

How can I contact Aytu Bioscience?

Aytu Bioscience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.